<DOC>
	<DOCNO>NCT01814163</DOCNO>
	<brief_summary>This pharmacogenomic study carboplatin , paclitaxel bevacizumab first line therapy patient non-squamous advanced non-small cell lung cancer .</brief_summary>
	<brief_title>Observational Post-authorization Studies Carboplatin , Paclitaxel Bevacizumab</brief_title>
	<detailed_description>This observational study prospectively follow post-authorization .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Patients sign inform consent inclusion study specify clinical treatment entail consent analysis biological sample tumor blood . 2 . Histologically confirm diagnosis advance non smallcell lung carcinoma , nonsquamous cell 3 . Patients age 18 year 4 . Patients candidate receive first line chemotherapy carboplatin , paclitaxel bevacizumab best therapeutic option . 5 . Evidence measurable disease per Response Evalutation Criteria Solid tumor ( RECIST ) 6 . Patients must avalaible clinical followup 7 . Patients follow hematologic/biochemical value : Absolute Neutrophil Count ANC &gt; 1500/µl . Platelets &gt; 100.000 /µl . Hemoglobine &gt; 10 g/dl . Bilirrubin &lt; 1.5 mg/dl . Aspartate aminotransfereasa ( AST ) Alanine transaminase ( ALT ) ≤ 3 x LSN , except case hepatic metastasis : upper 5 x LSN Creatinine clearance ≥ 45 ml/min . 1 . Previous treatment advance disease . Chemotherapy allow initial diagnosis patient limit disease patient receive adjuvant neadjuvant treatment 2. history haemoptysis ( define least half teaspoon 's emission red blood ) 3 month prior inclusion 3. evidence CT tumor cavitations , tumour invade abut major blood vessel 4 . Known suspected brain metastasis nontreated . 5 . Major surgery within 28 day start treatment . 6 . Minor surgery within 24 hour start treatment . 7 . Noncontrolled hypertension ( systolic &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg ) . 8 . Patients coronary disease uncontrolled arrhytmia , uncontrolled cerebrovascular disease clinical condition , judgment investigator , contraindicate patient 's participation study . 9 . History evidence bleed diathesis hereditary coagulopathy . 10 . Contraindication suspect allergy product investigation study : : paclitaxel , carboplatine bevacizumab . 11 . Patients pregnant breasfeeding . Women childbearing potencial must negative pregnancy test perform within 7 day onset treatment . 12 . Substance abuse clinical , psychological social condition undermine validity inform consent protocol compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>First line treatment</keyword>
	<keyword>Non small cell lung cancer , non squamous</keyword>
</DOC>